RITALIN-SR
Clinical safety rating: caution
Comprehensive clinical and safety monograph for RITALIN-SR (RITALIN-SR).
Methylphenidate is a central nervous system stimulant that blocks the reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their concentrations in the synaptic cleft.
| Metabolism | Primarily hepatic via carboxylesterase CES1A1 to inactive metabolite ritalinic acid; minor metabolism via CYP2D6. |
| Excretion | Primarily renal (90%) as metabolites including ritalinic acid, with 1-3% unchanged; minor biliary/fecal elimination. |
| Half-life | 2-3 hours for the immediate-release component; sustained-release formulation shows biphasic elimination with terminal half-life of 2-4 hours. |
| Protein binding | 10-15%, primarily to albumin. |
| Volume of Distribution | 0.5-1.5 L/kg; indicates extensive distribution into tissues. |
| Bioavailability | Oral sustained-release: 35-50% (first-pass metabolism); absolute bioavailability of immediate-release is 30-40%. |
| Onset of Action | Oral (sustained-release): 1-2 hours; peak effect at 4-6 hours. |
| Duration of Action | Approximately 7-8 hours for Ritalin-SR; clinical effect may last 6-10 hours depending on patient. |
20 mg orally twice daily, typically 30-45 minutes before breakfast and lunch; maximum 60 mg/day.
| Dosage form | TABLET, EXTENDED RELEASE |
| Renal impairment | No specific dose adjustment recommendations for GFR reduction; use with caution in severe renal impairment (CrCl <30 mL/min) due to potential for increased adverse effects. |
| Liver impairment | Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: avoid use (no data). |
| Pediatric use | Children 6 years and older: initially 0.3-0.6 mg/kg/dose orally twice daily, with a maximum of 2 mg/kg/day or 60 mg/day. Dosing should be individualised. |
| Geriatric use | Start at 10 mg once daily in the morning; increase slowly based on tolerability and response; monitor for cardiovascular effects, insomnia, and weight loss. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for RITALIN-SR (RITALIN-SR).
| Breastfeeding | Methylphenidate is excreted into human breast milk. M/P ratio is approximately 2.0. Relative infant dose is about 0.2-0.7% of maternal weight-adjusted dose. Limited data suggest low risk to infant, but monitor for agitation, insomnia, and poor feeding. American Academy of Pediatrics considers methylphenidate compatible with breastfeeding. |
| Teratogenic Risk | First trimester: Epidemiologic studies have not shown increased risk of major congenital anomalies with methylphenidate, but there are reports of increased risk of cardiac malformations (RR ~1.3). Second/third trimesters: Exposure may be associated with increased risk of preterm delivery, low birth weight, and neonatal withdrawal syndrome (irritability, feeding problems). Transient neonatal tachypnea and respiratory distress reported. |
■ FDA Black Box Warning
RITALIN-SR has a high potential for abuse and dependence. Prolonged use may lead to drug dependence. Misuse can cause sudden death or serious cardiovascular events.
| Serious Effects |
["Hypersensitivity to methylphenidate or any component","Marked anxiety, tension, and agitation","Glaucoma","Motor tics or family history of Tourette's syndrome","Concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuation"]
| Precautions | ["Serious cardiovascular events including sudden death in patients with pre-existing structural cardiac abnormalities","Psychiatric adverse events including exacerbation of pre-existing psychosis, mania, or aggression","Seizures: risk may be increased in patients with prior seizure history or EEG abnormalities","Priapism: prolonged erections requiring immediate medical attention","Peripheral vasculopathy including Raynaud's phenomenon","Long-term suppression of growth in pediatric patients","Hematologic effects: monitor complete blood counts with differential during prolonged use"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal weight gain, blood pressure, heart rate, and assess for anxiety or insomnia. Fetal monitoring: Serial growth ultrasounds (growth restriction risk), fetal heart rate monitoring, and neonatal assessment for withdrawal symptoms (irritability, tachypnea) after delivery. |
| Fertility Effects | Animal studies show reduced fertility with high doses (impaired spermatogenesis in males, prolonged estrous cycles in females). Human data limited, but no consistent evidence of impaired fertility. Use may be associated with decreased libido or erectile dysfunction, potentially affecting conception. |